β-cell induction in vivo in severely diabetic male mice by changing the circulating levels and pattern of the ratios of estradiol to androgens

Endocrinology (United States)

Volumn 155, Issue 10, 2014, Pages 3829-3842

  Inada, Akari ^a   Inada, Oogi ^a   Fujii, Nobuharu L ^b   Fujishima, Kei ^a   Inai, Tetsuichiro ^a,c   Fujii, Hiroshi ^a   Sueishi, Katsuo ^a   Kurachi, Kotoku ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN UNIVERSITY   (Japan)

^c FUKUOKA DENTAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTRADIOL; GLUCOSE; TRANSCRIPTION FACTOR PDX 1; CREM PROTEIN, MOUSE; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; GLUCOSE BLOOD LEVEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL STRUCTURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ORCHIECTOMY; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; SEX DIFFERENCE; ANIMAL; BLOOD; C57BL MOUSE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TRANSGENIC MOUSE;

ANDROGENS; ANIMALS; BLOOD GLUCOSE; CELL PROLIFERATION; CYCLIC AMP RESPONSE ELEMENT MODULATOR; DIABETES MELLITUS, EXPERIMENTAL; ESTRADIOL; FEMALE; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; ORCHIECTOMY; SEVERITY OF ILLNESS INDEX;

EID: 84907202612     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1254     Document Type: Article

References (44)

1. Weir GC, Bonner-Weir S. Five stages of evolving-cell dysfunction during progression to diabetes. Diabetes. 2004;53(suppl 3):S16-S21.
2. Inada A, Hamamoto Y, Tsuura Y, et al. Overexpression of inducible cyclic AMP early repressor inhibits transactivation of genes and cell proliferation in pancreatic cells. Mol Cell Biol. 2004;24(7):2831-2841.
3. Foulkes NS, Borrelli E, Sassone-Corsi P. CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell. 1991;64(4):739-749.
4. Foulkes NS, Borjigin J, Snyder SH, Sassone-Corsi P. Transcriptional control of circadian hormone synthesis via the CREM feedback loop. Proc Natl Acad Sci USA. 1996;93(24):14140-14145.
5. Molina CA, Foulkes NS, Lalli E, Sassone-Corsi P. Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell. 1993; 75(5):875-886.
6. Stehle JH, Foulkes NS, Molina CA, Simonneaux V, Pévet P, Sassone-Corsi P. Adrenergic signals direct rhythmic expression of transcriptional repressor CREM in the pineal gland. Nature. 1993; 365(6444):314-320.
7. Inada A, Someya Y, Yamada Y, et al. The cyclic AMP response element modulator family regulates the insulin gene transcription by interacting with transcription factor IID. J Biol Chem. 1999; 274(30):21095-21103.
8. Inada A, Weir GC, Bonner-Weir S. Induced ICER I down-regulates cyclin A expression and cell proliferation in insulin-producing cells. Biochem Biophys Res Commun. 2005;329(3):925-929.
9. Inada A, Nagai K, Arai H, et al. Establishment of a diabetic mouse model with progressive diabetic nephropathy. Am J Pathol. 2005; 167(2):327-336.
10. Inada A, Kanamori H, Arai H, et al. A model for diabetic nephropathy: advantages of the inducible cAMP early repressor transgenic mouse over the streptozotocin-induced diabetic mouse. J Cell Physiol. 2008;215(2):383-391.
11. Inada A, Arai H, Nagai K, et al. Gender difference in ICER I transgenic diabetic mouse. Biosci Biotechnol Biochem. 2007;71(8): 1920-1926.
12. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331(2):1056-1061.
13. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80(12):3689-3698.
14. Bryzgalova G, Gao H, Ahren B, et al. Evidence that oestrogen receptor-plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver. Diabetologia. 2006; 49(3):588-597.
15. Andersson B, Mattsson LA, Hahn L, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulindependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82(2): 638-643.
16. Brussaard HE, Gevers Leuven JA, Frölich M, Kluft C, Krans HM. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia. 1997;40(7):843-849.
17. Spencer CP, Godsland IF, Cooper AJ, Ross D, Whitehead MI, Stevenson JC. Effects of oral and transdermal 17-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism. 2000; 49(6):742-747.
18. Friday KE, Dong C, Fontenot RU. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2001;86(1): 48-52.
19. Geisler JG, Zawalich W, Zawalich K, et al. Estrogen can prevent or reverse obesity and diabetes in mice expressing human islet amyloid polypeptide. Diabetes. 2002;51(7):2158-2169.
20. Le May C, Chu K, Hu M, et al. Estrogens protect pancreatic-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci USA. 2006;103(24):9232-9237.
21. Liu S, Le May C, Wong WP, et al. Importance of extranuclear estrogen receptor-and membraneGprotein-coupled estrogen receptor in pancreatic islet survival. Diabetes. 2009;58(10):2292-2302.
22. Nadal A, Ropero AB, Laribi O, Maillet M, Fuentes E, Soria B. Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen receptor and estrogen receptor . Proc Natl Acad Sci USA. 2000;97(21):11603-11608.
23. Tibblin G, Adlerberth A, Lindstedt G, Björntorp P. The pituitarygonadal axis and health in elderly men: a study of men born in 1913. Diabetes. 1996;45(11):1605-1609.
24. Mauvais-Jarvis F. Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol Metab. 2011;22(1):24-33.
25. Lin HY, Xu Q, Yeh S, Wang RS, Sparks JD, Chang C. Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes. 2005;54(6):1717-1725.
26. Inoue T, Zakikhani M, David S, Algire C, Blouin MJ, Pollak M. Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man. Prostate. 2010;70(15):1628-1635.
27. Barkley MS, Geschwind II, Bradford GE. The gestational pattern of estradiol, testosterone and progesterone secretion in selected strains of mice. Biol Reprod. 1979;20(4):733-738.
28. Nishimura W, Kondo T, Salameh T, et al. A switch from MafB to MafA expression accompanies differentiation to pancreatic-cells. Dev Biol. 2006;293(2):526-539.
29. Hewitt SC, Couse JF, Korach KS. Estrogen receptor transcription and transactivation: estrogen receptor knockout mice-what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res. 2000;2(5):345-352.
30. Korach KS, Muldoon TG. Inhibition of anterior pituitary estrogenreceptor complex formation by low-affinity interaction with 5-dihydrotestosterone. Endocrinology. 1975;97(1):231-236.
31. Tomiyoshi Y, Sakemi T, Aoki S, Miyazono M. Different effects of castration and estrogen administration on glomerular injury in spontaneously hyperglycemic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Nephron. 2002;92(4):860-867.
32. Bonner-Weir S, Guo L, Ouziel-Yahalom L, et al. Islet neogenesis: a possible pathway for-cell replenishment. Rev Diabetic Studies. 2012;9(4):407-416.
33. Kyrmizi I, Hatzis P, Katrakili N, Tronche F, Gonzalez FJ, Talianidis I. Plasticity and expanding complexity of the hepatic transcription factor network during liver development. Genes Dev. 2006;20(16): 2293-2305.
34. Annicotte JS, Fayard E, Swift GH, et al. Pancreatic-duodenal homeobox 1 regulates expression of liver receptor homolog 1 during pancreas development. Mol Cell Biol. 2003;23(19):6713-6724.
35. Mellado-Gil JM, Cobo-Vuilleumier N, Gauthier BR. Islet-cell mass preservation and regeneration in diabetes mellitus: four factors with potential therapeutic interest. J Transplant. 2012;2012:230870.
36. Sabbah M, Courilleau D, Mester J, Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci USA. 1999;96(20):11217-11222.
37. Oliver-Krasinski JM, Kasner MT, Yang J, et al. The diabetes gene Pdx1 regulates the transcriptional network of pancreatic endocrine progenitor cells in mice. J Clin Invest. 2009;119(7):1888-1898.
38. Gerrish K, Gannon M, Shih D, et al. Pancreatic-cell-specific transcription of the pdx-1 gene. The role of conserved upstream control regions and their hepatic nuclear factor 3 sites. J Biol Chem. 2000; 275(5):3485-3492.
39. Rausa FM, Galarneau L, Bélanger L, Costa RH. The nuclear receptor fetoprotein transcription factor is coexpressed with its target gene HNF-3 in the developing murine liver, intestine and pancreas. Mech Dev. 1999;89(1-2):185-188.
40. Guo L, Inada A, Aguayo-Mazzucato C, et al. PDX1 in ducts is not required for postnatal formation of-cells but is necessary for their subsequent maturation. Diabetes. 2013;62(10):3459-3468.
41. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol. 1992;2(5):675-682.
42. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335-4343.
43. Bojesen A, Kristensen K, Birkebaek NH, et al. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care. 2006;29(7): 1591-1598.
44. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106(3):581-588.